These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 15326486)
1. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Shinohara S; Rothstein JL Oncogene; 2004 Sep; 23(45):7571-9. PubMed ID: 15326486 [TBL] [Abstract][Full Text] [Related]
2. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Puxeddu E; Knauf JA; Sartor MA; Mitsutake N; Smith EP; Medvedovic M; Tomlinson CR; Moretti S; Fagin JA Endocr Relat Cancer; 2005 Jun; 12(2):319-34. PubMed ID: 15947106 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Russell JP; Shinohara S; Melillo RM; Castellone MD; Santoro M; Rothstein JL Oncogene; 2003 Jul; 22(29):4569-77. PubMed ID: 12881713 [TBL] [Abstract][Full Text] [Related]
4. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells. Fiore AP; Fuziwara CS; Kimura ET Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779 [TBL] [Abstract][Full Text] [Related]
5. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Burniat A; Jin L; Detours V; Driessens N; Goffard JC; Santoro M; Rothstein J; Dumont JE; Miot F; Corvilain B Endocrinology; 2008 Oct; 149(10):5107-17. PubMed ID: 18583418 [TBL] [Abstract][Full Text] [Related]
6. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Wang J; Knauf JA; Basu S; Puxeddu E; Kuroda H; Santoro M; Fusco A; Fagin JA Mol Endocrinol; 2003 Jul; 17(7):1425-36. PubMed ID: 12690093 [TBL] [Abstract][Full Text] [Related]
7. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322 [TBL] [Abstract][Full Text] [Related]
8. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice. Powell DJ; Russell JP; Li G; Kuo BA; Fidanza V; Huebner K; Rothstein JL Oncogene; 2001 May; 20(25):3235-46. PubMed ID: 11423973 [TBL] [Abstract][Full Text] [Related]
9. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM Oncogene; 2004 Aug; 23(35):5958-67. PubMed ID: 15184868 [TBL] [Abstract][Full Text] [Related]
10. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice. Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036 [TBL] [Abstract][Full Text] [Related]
11. Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland. Prost G; Bernier-Valentin F; Croset M; Rousset B Endocr Relat Cancer; 2009 Sep; 16(3):873-84. PubMed ID: 19509066 [TBL] [Abstract][Full Text] [Related]
12. RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas? Musholt PB; Imkamp F; von Wasielewski R; Schmid KW; Musholt TJ Surgery; 2003 Dec; 134(6):881-9; discussion 889. PubMed ID: 14668719 [TBL] [Abstract][Full Text] [Related]
13. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. Knauf JA; Ouyang B; Croyle M; Kimura E; Fagin JA Oncogene; 2003 Oct; 22(44):6830-8. PubMed ID: 14534528 [TBL] [Abstract][Full Text] [Related]
14. A thyroid tumor-specific antigen formed by the fusion of two self proteins. Powell DJ; Eisenlohr LC; Rothstein JL J Immunol; 2003 Jan; 170(2):861-9. PubMed ID: 12517951 [TBL] [Abstract][Full Text] [Related]
15. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Miyagi E; Braga-Basaria M; Hardy E; Vasko V; Burman KD; Jhiang S; Saji M; Ringel MD Mol Carcinog; 2004 Oct; 41(2):98-107. PubMed ID: 15378648 [TBL] [Abstract][Full Text] [Related]
18. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice. Cho JY; Sagartz JE; Capen CC; Mazzaferri EL; Jhiang SM Oncogene; 1999 Jun; 18(24):3659-65. PubMed ID: 10380889 [TBL] [Abstract][Full Text] [Related]
19. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225 [TBL] [Abstract][Full Text] [Related]
20. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Borrello MG; Alberti L; Fischer A; Degl'innocenti D; Ferrario C; Gariboldi M; Marchesi F; Allavena P; Greco A; Collini P; Pilotti S; Cassinelli G; Bressan P; Fugazzola L; Mantovani A; Pierotti MA Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14825-30. PubMed ID: 16203990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]